aldo-keto reductase family 1 member B10Genealiases: AKR1B11 · AKR1B12 · ALDRLn · ARL-1 · ARL1 · HIS
Q-omics provides the consensus-scored AKR1B10 profile across patient tissues and cancer cell-line models. AKR1B10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKR1B10 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, AKR1B10 protein abundance shows 16,809 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where AKR1B10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1B10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1B10 survival associations across molecular data types. AKR1B10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1B10 RNA expression–survival associations across cancer types. High AKR1B10 expression shows unfavorable associations in KIRC, UVM, KICH, LIHC and KIRP, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKR1B10 RNA expression.
This table summarizes AKR1B10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for AKR1B10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1B10 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRP, LUSC, LUAD and LIHC. The COAD box plot shows higher AKR1B10 RNA expression in normal versus tumor tissue (log2 FC = −4.531, t-test p < 0.001).
This table shows molecular features associated with AKR1B10 in patient tissues and cancer cell lines. In patient samples, AKR1B10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR1B10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
